Currently, there is no cure for Alzheimer's disease.
Researchers are continually testing the effectiveness of various drug therapies that will control symptoms; slow, reduce and/or reverse mental and behavioral symptoms; and prevent or halt the disease. The historic "National Plan to Address Alzheimer's Disease," released by the U.S. Department of Health and Human Services in May 2012 and updated annually, calls for preventing and effectively treating Alzheimer's disease by 2025.
The U.S. Food and Drug Administration (FDA) has approved several medications for the treatment of Alzheimer's disease.
Currently available are:
NAMENDA XR® (memantine hydrochloride) extended-release capsules are approved for the treatment of moderate to severe Alzheimer's disease. NAMENDA XR is available by prescription only.
NAMENDA XR® is a once-a-day medication approved for moderate to severe Alzheimer's disease that can be used alone or in combination with an acetylcholinesterase inhibitor (AChEI). Because NAMENDA XR works differently than other Alzheimer's treatments, combination therapy with NAMENDA XR and an AChEI may help improve your loved one's overall function and cognition.
Adding NAMENDA XR to an AChEI may also help slow down the worsening of your loved one's symptoms for a while. Generally, patients with moderate Alzheimer's disease experience the fastest rate of decline. If your loved one has been diagnosed with moderate to severe Alzheimer's disease, ask the doctor about the benefits of adding NAMENDA XR to your loved one's treatment for Alzheimer's.
Namzaric is approved for the treatment of moderate to severe Alzheimer's disease in patients who are currently taking and can continue to take certain doses of both NAMENDA® (memantine HCI) or NAMENDA XR® (memantine HCl) extended release and donepezil HCI, the active ingredient in Aricept®. NAMZARIC is available by prescription only.
If your loved one is already taking NAMENDA XR® (memantine hydrochloride) extended release and Aricept (donepezil HCl) 10 mg, ask their doctor if once-a-day NAMZARIC may be the right treatment for them.
NAMENDA® (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. NAMENDA is available by prescription only.
Therapy begins at a low dose (5 mg per day) of NAMENDA and is gradually increased until the recommended target dose (10 mg, twice daily) is reached. A recommended dosing schedule for beginning NAMENDA therapy is provided below.
Once the recommended target dose of NAMENDA (10 mg, twice daily) has been reached, people taking NAMENDA can continue with that daily regimen unless instructed otherwise by their doctors. (For patients with severe renal impairment, 5 mg twice daily is the recommended dose.) As with all types of prescription medications, do not stop taking NAMENDA without first talking to a doctor.
ARICEPT 5mg and 10 mg are indicated for mild to moderate Alzheimer's disease, and ARICEPT 10 mg and 23 mg are indicated for moderate to severe Alzheimer's disease
Approved in pill and patch form for mild to moderate Alzheimer's disease, and in a higher dosage Exelon Patch for severe Alzheimer's disease
Approved for mild to moderate Alzheimer's disease
Some of these medications can be used alone or in combination, and may help slow progression of symptoms and improve quality of life.
These medications come in various dosages; dispensing requirements (i.e., once or twice a day); formulations (i.e., extended release); and forms, including tablet, capsule, liquid and patch.
Before taking medications, it is advisable to speak with a healthcare provider regarding past and present medical conditions; allergies; and possible side effects.
Currently, research supports behavioral management interventions for individuals with dementia, as well as education, counseling and other support services for caregivers.
The National Institute on Aging, in concert with the FDA, tracks private- and government-sponsored clinical trials; contact the Alzheimer's Disease Education and Referral Center (www.alzheimers.org/trials or 800-438-4380). AFA also lists clinical trials; click here.
For more information, connect with the Alzheimer’s Foundation of America’s licensed social workers. Click here or call 866.232.8484. Real People. Real Care.